2-(4-氟苯基)-5-甲基吡啶 | 85237-65-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(4-氟苯基)-5-甲基吡啶
• 英文名称: 2-(4-fluorophenyl)-5-methylpyridine
• CAS: 85237-65-6
• 化学式: C₁₂H₁₀FN
• mdl: MFCD09037512
• 分子量: 187.217
• InChiKey: WSVYYUKIXFSDTE-UHFFFAOYSA-N

物化性质

• 熔点：
  58-59 °C
• 沸点：
  285.6±25.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• WGK Germany：
  3
• 危险性防范说明：
  P264,P280,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313
• 危险性描述：
  H315,H319
• 储存条件：
  存储条件：2-8℃，惰性气体环境中。

反应信息

• 作为反应物：
  描述：

  2-(4-氟苯基)-5-甲基吡啶 以 乙二醇甲醚 、 水 、 乙二醇 、 乙腈 为溶剂， 生成 (2,2'-dipyridyl)-bis-(5-methyl-2-(4-fluorophenyl)pyridine(-1H))-iridium(III) chloride
  参考文献：
  名称：

  Accelerated Luminophore Discovery through Combinatorial Synthesis

  摘要：

  A method for accelerating the discovery of ionic luminophores using combinatorial techniques is reported. The photophysical properties of the resulting transition-metal-based chromophores were compared against a series of analogous, traditionally prepared species. The strong overlap between these two sets confirms the identity of the parallel synthesis products and supports the truthfulness of the combinatorial results. Further support for the combinatorial method comes from the adherence of these complexes to the energy gap law. The relationship between the structure of a complex and its photophysical properties was also considered, and static DFT calculations were used to assess whether it is feasible to predict the luminescent behavior of novel materials.

  DOI：

  10.1021/ja047156+
• 作为产物：
  描述：

  2-溴-4'-氟苯乙酮 在 乙酸铵 作用下， 以 甲醇 为溶剂， 反应 15.0h， 生成 2-(4-氟苯基)-5-甲基吡啶
  参考文献：
  名称：

  Accelerated Luminophore Discovery through Combinatorial Synthesis

  摘要：

  A method for accelerating the discovery of ionic luminophores using combinatorial techniques is reported. The photophysical properties of the resulting transition-metal-based chromophores were compared against a series of analogous, traditionally prepared species. The strong overlap between these two sets confirms the identity of the parallel synthesis products and supports the truthfulness of the combinatorial results. Further support for the combinatorial method comes from the adherence of these complexes to the energy gap law. The relationship between the structure of a complex and its photophysical properties was also considered, and static DFT calculations were used to assess whether it is feasible to predict the luminescent behavior of novel materials.

  DOI：

  10.1021/ja047156+

文献信息

• [EN] TASK CHANNEL ANTAGONISTS<br/>[FR] ANTAGONISTES DES CANAUX TASK
  申请人：MERCK SHARP & DOHME

  公开号：WO2011106276A1

  公开（公告）日：2011-09-01

  This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders which have TASK-1 and/or TASK-3-related damage as a secondary cause.

  这项发明涉及TASK-1和/或TASK-3拮抗剂及/或其药用盐、用于治疗和预防由TASK-1和/或TASK-3的激活或被激活引起的疾病，以及由TASK-1和/或TASK-3相关损伤作为次要原因的疾病的组合物和方法。
• IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES
  申请人：Bartolomé-Nebreda José Manuel

  公开号：US20120329792A1

  公开（公告）日：2012-12-27

  The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

  本发明涉及新型咪唑并[1,2-a]吡嗪衍生物，其为磷酸二酯酶10（PDE10）的抑制剂，并且适用于治疗或预防涉及PDE10酶的神经、精神和代谢性疾病。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物或药物组合物预防或治疗神经、精神和代谢性疾病和疾病。
• Photo-induced thiolate catalytic activation of inert Caryl-hetero bonds for radical borylation
  作者：Shun Wang、Hua Wang、Burkhard König

  DOI：10.1016/j.chempr.2021.04.016

  日期：2021.6

  the activation of bonds with high bond dissociation energy and to substrates with high reduction potentials. Herein, we introduce a novel photocatalytic strategy for the activation of inert substituted arenes for aryl borylation by using thiolate as a catalyst. This catalytic system exhibits strong reducing ability and engages non-activated Caryl–F, Caryl–X, Caryl–O, Caryl–N, and Caryl–S bonds in productive

  目前正致力于获得具有高氧化还原能力的光氧化还原催化剂。然而，将目前建立的方法应用于具有高键离解能的键的活化和具有高还原电位的基材仍然具有挑战性。在此，我们介绍了一种新的光催化策略，通过使用硫醇盐作为催化剂来活化惰性取代芳烃以进行芳基硼化。该催化体系具有很强的还原能力，可与未活化的C芳基-F、C芳基-X、C芳基-O、C芳基-N和C芳基结合-S 键用于生产性自由基硼化反应，从而扩大了可用的芳基自由基前体范围。尽管具有很高的还原能力，但该方法具有广泛的底物范围和良好的官能团耐受性。光谱研究和控制实验表明，电荷转移复合物的形成是激活底物的关键步骤。
• Hydrodefluorinations by low-valent niobium catalyst
  作者：Kohei Fuchibe、Yoshitaka Ohshima、Ken Mitomi、Takahiko Akiyama

  DOI：10.1016/j.jfluchem.2007.06.003

  日期：2007.10

  Catalytic hydrodefluorinations of organofluorine compounds by low-valent niobium catalyst were developed. In the presence of niobium(V) chloride (typically, 5 mol%), fluorobenzenes, α,α,α-trifluorotoluenes and (trifluoromethyl)pyridines were hydrodefluorinated with lithium aluminum hydride to give the corresponding benzenes, toluenes and methylpyridines in good yields, respectively.

  研究了低价铌催化剂对有机氟化合物的催化加氢脱氟化氢反应。在氯化铌（V）（通常为5 mol％）的存在下，用氢化铝锂将氟苯，α，α，α-三氟甲苯和（三氟甲基）吡啶加氢脱氟化氢，以高收率得到相应的苯，甲苯和甲基吡啶，分别。
• Pyrrolidines
  申请人：Dack Kevin N.

  公开号：US20100120793A1

  公开（公告）日：2010-05-13

  This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutically acceptable derivatives thereof, to their use in medicine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds of formula (I) are useful for the treatment of EP2-mediated conditions, such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome.

  这项发明涉及一类式(I)的吡咯烷化合物及其药学上可接受的衍生物，它们在医学上的应用，含有它们的组合物，以及它们的制备方法。它还涉及用于制备这类化合物和衍生物的中间体。特别是式(I)的化合物对于治疗EP2介导的疾病非常有用，如子宫内膜异位症、子宫肌瘤（平滑肌瘤）、月经过多、子宫腺肌病、原发性和继发性痛经（包括性交疼痛、排便疼痛和慢性盆腔疼痛症状）、慢性盆腔疼痛综合征。